Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Dermatology Physician in Sacramento, CA
NPI: 1043250145Primary Employer
Golden State Dermatology Associates, Inc.
goldenstatedermatology.com
HQ Phone
Get M.D. Emil's Phone Numberphone_androidMobile
Get M.D. Emil's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1977 - 2026
American Board of Dermatology
Dermatology
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 1976
Lahey Clinic
Residency • Dermatology
1979 - 1980
Mass General Brigham/Massachusetts General Hospital/Beth Israel Deaconess Medical Center/Brigham and Women's Hosp
Residency • Dermatology
1978 - 1979
Stanford Health Care-Sponsored Stanford University
Residency • Internal Medicine
1977 - 1978
University of Texas Southwestern Medical Center
Internship • Internal Medicine
1976 - 1977
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 1,426 | 2,508 |
| 2 | 17000Destruction of skin growth | 950 | 1,356 |
| 3 | 17003Destruction of 2-14 skin growths | 746 | 3,940 |
| 4 | 11102Tangential biopsy of single skin lesion | 646 | 769 |
| 5 | 99212Established patient outpatient visit, total time 10-19 minutes | 328 | 488 |
A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide.
Authors: Lawrence Eichenfield, Diane Thiboutot
Journal: Cutis
The clinical impact of vehicle technology using a patented formulation of benzoyl peroxide 5%/clindamycin 1% gel: comparative assessments of skin tolerability and evaluation of combination use with a topical retinoid.
Authors: James Q Del Rosso, Emil Tanghetti
Publication Date: 2006-02
Lead Sponsor: Cynosure, Inc.
Intervention / Treatment: DEVICE: PicoSure Device, DRUG: Topical Cosmeceuticals, DEVICE: PicoSure Pro Device
Lead Sponsor: Cutera Inc.
Intervention / Treatment: DEVICE: Excel V™ Laser & Micro-Lens Array Attach
Lead Sponsor: Cassiopea SpA
Intervention / Treatment: DRUG: Vehicle cream, DRUG: CB-03-01 cream, 1%